Generation Bio Posts 81% Q2 Revenue Drop

Generation Bio (NASDAQ:GBIO), a biotechnology firm developing cell-targeted siRNA therapeutics for autoimmune diseases, released its second quarter earnings on August 12, 2025. The main news was a deeper-than-expected net loss (GAAP) and a steep drop in collaboration revenue, alongside the announcement of a major shift in company strategy—a 90% workforce reduction and a formal strategic review to explore mergers or asset sales. Net loss per share (GAAP) was $(3.12), underperforming the $(2.85) GAAP loss analysts expected. Revenue (GAAP) came in at $0.77 million, significantly below the $2.51 million revenue estimate and down from $4.09 million (GAAP) in the prior year. The quarter reflects a challenging period for the company, marked by strategic uncertainty and a notable pivot away from in-house development. Source: Analyst estimates for the quarter provided by FactSet. Generation Bio is a biotechnology company aiming to treat autoimmune disorders by delivering gene-silencing molecules to T cells, a specific type of immune cell. Its platform centers on a proprietary delivery system called cell-targeted lipid nanoparticles (ctLNP), which are designed to carry short interfering RNA (siRNA) and selectively silence genes inside T cells without affecting other cells.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool